This study looks at a new treatment called Arlocabtagene Autoleucel (BMS-986393). It’s a type of therapy called CAR T Cell Therapy aimed at fighting a blood cancer called multiple myeloma, which comes back or doesn’t respond to other treatments. Multiple myeloma is cancer that affects a person's plasma cells, a type of white blood cell that helps fight infections. The study checks if this treatment is safe and how well it works.
To join, you must have tried at least three different types of treatments for multiple myeloma and seen your disease get worse. You should be in good health overall (ECOG performance status of 0 or 1). You cannot join if your cancer has affected your brain or if you have an active infection.
- Participants will undergo screening to confirm eligibility.
- Study duration and number of visits will be explained during enrollment.
- Potential risks and benefits will be discussed with participants.
How understandable was the trial content above?
Hard to understand
Easy to understand